Stock Analiz

Adagene Inc. ADAG

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$1.71Market cap $113M
Open the interactive analysis →

Adagene Inc. (ADAG) is a healthcare company listed in the US with a market value of about $113M. In fiscal year 2025 it had revenue of $8M and net income of -$18M, a net margin of -229.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 61% a year, a 5-year average ROIC of -43%.

About Adagene

Adagene is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $2M in 2018 to $8M in 2025, growth of about 26.1% a year. It was profitable in 0 of the last 8 years in our data. It spends 287% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S14.7
P/B3.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-13.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)7332.8%
Revenue growth (5 yrs, per year)61.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-6860.1%
ROIC (5-yr avg.)-43.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue$8M$103204$18M$9M$10M$700913$480000$2M
Net income-$18M-$33M-$19M-$80M-$73M-$42M-$16M-$15M
Free cash flow-$16M-$30M-$29M-$49M-$46M-$29M-$18M-$15M
EPS (diluted)$-0.27$-0.51$-0.29$-1.21$-1.11$-0.64$-0.25$-0.23
Net margin-229.6%-32386.5%-104.6%-860.6%-719.2%-6048.9%-3423.4%-1010.2%
ROIC-50.7%-52.1%-20.2%-59.7%-34.8%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Adagene pay a dividend?

Not currently.

Is Adagene a good stock to buy?

We do not give buy or sell advice. Adagene scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.